Top

Published in:

01-02-2019 | Original Article

Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines

Authors: Ajimu Keremu, Abudusaimi Aimaiti, Zhilin Liang, Xiaoguang Zou

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2019

Abstract

Histone deacetylases (HDACs), initially described as histone modifiers, have more recently been verified to target various other proteins unrelated to the chromatin environment. On this basis, findings of the current study demonstrates that the pharmacological or genetic abrogation of HDAC6 in osteosarcoma cell lines down-regulates the expression of program death receptor ligand-1 (PD-L1), an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T cells. As shown by our results, the mechanism by which HDAC6 regulated PD-L1 expression was mediated by the transcription factor STAT3. In addition, we observed that selective HDAC6 inhibitors could inhibit tumor progression in vivo. Crucially, these results provide an essential pre-clinical rationale and justification for the necessity of further research on HDAC6 inhibitors as potential immuno-modulatory agents in osteosarcoma.

Available only for authorised users

Omer N, Le Deley MC, Piperno-Neumann S, Marec-Berard P, Italiano A, Corradini N, Bellera C, Brugieres L, Gaspar N (2017) Phase-II trials in osteosarcoma recurrences: a systematic review of past experience. Eur J Cancer 75:98–108. https://doi.org/10.1016/j.ejca.2017.01.005 CrossRefPubMed

Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P (2016) Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy 8(10):1233–1244. https://doi.org/10.2217/imt-2016-0048 CrossRefPubMed

Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A (2012) Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 90(1):55–65. https://doi.org/10.1038/icb.2011.96 CrossRefPubMed

Tomasi TB, Magner WJ, Khan AN (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother CII 55(10):1159–1184. https://doi.org/10.1007/s00262-006-0164-4 CrossRefPubMed

Villagra A, Sotomayor EM, Seto E (2010) Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29(2):157–173. https://doi.org/10.1038/onc.2009.334 CrossRefPubMed

Dallavalle S, Pisano C, Zunino F (2012) Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol 84(6):756–765. https://doi.org/10.1016/j.bcp.2012.06.014 CrossRefPubMed

Wang Z, Hu P, Tang F, Lian H, Chen X, Zhang Y, He X, Liu W, Xie C (2016) HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett 379(1):134–142. https://doi.org/10.1016/j.canlet.2016.06.001 CrossRefPubMed

Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A (2015) Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 9(7):1447–1457. https://doi.org/10.1016/j.molonc.2015.04.002 CrossRefPubMedPubMedCentral

Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, Villagra A, Sotomayor EM (2014) A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol 193(6):2850–2862. https://doi.org/10.4049/jimmunol.1302778 CrossRefPubMed

10.

Tu B, Du L, Fan QM, Tang Z, Tang TT (2012) STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325(1):80–88. https://doi.org/10.1016/j.canlet.2012.06.006 CrossRefPubMed

11.

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064–5074. https://doi.org/10.1158/1078-0432.CCR-13-3271 CrossRefPubMedPubMedCentral

12.

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentral

13.

Lussier DM, Johnson JL, Hingorani P, Blattman JN (2015) Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3:21. https://doi.org/10.1186/s40425-015-0067-z CrossRefPubMedPubMedCentral

14.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Johrens K (2016) Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7(2):1486–1499. https://doi.org/10.18632/oncotarget.6429 CrossRefPubMed

15.

Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C (2016) PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 7(17):24269–24283. https://doi.org/10.18632/oncotarget.8169 CrossRefPubMedPubMedCentral

16.

Chen S, Wang RX, Liu Y, Yang WT, Shao ZM (2017) PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Int J Cancer 140(6):1384–1395. https://doi.org/10.1002/ijc.30552 CrossRefPubMed

17.

Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 55(22):9891–9899. https://doi.org/10.1021/jm301098e CrossRefPubMedPubMedCentral

18.

Wang WB, Yen ML, Liu KJ, Hsu PJ, Lin MH, Chen PM, Sudhir PR, Chen CH, Chen CH, Sytwu HK, Yen BL (2015) Interleukin-25 mediates transcriptional control of PD-L1 via STAT3 in multipotent human mesenchymal stromal cells (hMSCs) to suppress Th17 responses. Stem Cell Rep 5(3):392–404. https://doi.org/10.1016/j.stemcr.2015.07.013 CrossRef

19.

Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, Asamura H, Kawaishi M, Kuwano K, Ochiya T (2015) The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Molecular therapy: the journal of the American Society of Gene Therapy 23(4):717–727. https://doi.org/10.1038/mt.2015.10 CrossRef

20.

Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L (2014) EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 5(23):12189–12202. https://doi.org/10.18632/oncotarget.2608 CrossRefPubMedPubMedCentral

21.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

22.

Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci 130(12):987–1003. https://doi.org/10.1042/CS20160084 CrossRef

23.

Serrador JM, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Sanchez-Madrid F (2004) HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 20(4):417–428CrossRefPubMed

24.

Beier UH, Akimova T, Liu Y, Wang L, Hancock WW (2011) Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol 23(5):670–678. https://doi.org/10.1016/j.coi.2011.07.002 CrossRefPubMedPubMedCentral

25.

Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KSM, Montecino M, Kozikowsh A, Pinilla-Ibarz J, Sarnaik A, Seto E, Weber J, Sotomayor EM, Villagra A (2016) Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol Oncol 10(5):735–750. https://doi.org/10.1016/j.molonc.2015.12.012 CrossRefPubMedCentral

26.

Bramsen JB, Kjems J (2011) Chemical modification of small interfering RNA. Methods Mol Biol 721:77–103. https://doi.org/10.1007/978-1-61779-037-9_5 CrossRefPubMed

27.

Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417(6887):455–458. https://doi.org/10.1038/417455a CrossRefPubMed

28.

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI (2008) Activated stat-3 in melanoma. Cancer Control 15(3):196–201CrossRefPubMed

29.

Ray S, Lee C, Hou T, Boldogh I, Brasier AR (2008) Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 36(13):4510–4520. https://doi.org/10.1093/nar/gkn419 CrossRefPubMedPubMedCentral

30.

Yuan ZL, Guan YJ, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307(5707):269–273. https://doi.org/10.1126/science.1105166 CrossRefPubMed

31.

Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, Zheng S, Liang C, Liu J, Lu C, Liu B, Lu J, Wang L, Lu A, Zhang G (2016) Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int J Mol Sci 17(4):506. https://doi.org/10.3390/ijms17040506 CrossRefPubMedPubMedCentral

32.

Yang J, Zhang W (2013) New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 25(4):398–406. https://doi.org/10.1097/CCO.0b013e3283622c1b CrossRefPubMed

33.

Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother CII 66(5):551–564. https://doi.org/10.1007/s00262-017-1954-6 CrossRefPubMed

34.

Lussier DM, O’Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN (2015) Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 38(3):96–106. https://doi.org/10.1097/CJI.0000000000000065 CrossRefPubMedPubMedCentral

35.

Burgess M, Tawbi H (2015) Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol 16(6):26. https://doi.org/10.1007/s11864-015-0345-5 CrossRefPubMed

36.

Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, Bhat JA, Najar RA, Qazi AK, Zargar MA, Singh SK, Saxena AK (2012) Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol 31(Suppl 1):S62–S71. https://doi.org/10.1089/dna.2011.1575 CrossRefPubMed

37.

Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, Chai Y (2016) Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget 7(15):19863–19883. https://doi.org/10.18632/oncotarget.7887 CrossRefPubMedPubMedCentral

38.

Yuan J, Zhang F, Niu R (2015) Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep 5:17663. https://doi.org/10.1038/srep17663 CrossRefPubMedPubMedCentral

39.

Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100(9):5336–5341. https://doi.org/10.1073/pnas.0931259100 CrossRefPubMedPubMedCentral

40.

Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunological reviews 236:219–242. https://doi.org/10.1111/j.1600-065X.2010.00923.x CrossRefPubMedPubMedCentral

Title: Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
Authors: Ajimu Keremu
Abudusaimi Aimaiti
Zhilin Liang
Xiaoguang Zou
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3721-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy

Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals

Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B

Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

Keynote webinar | Spotlight on antibody–drug conjugates in cancer